rac cis-Moxifloxacin-d4 (hydrochloride)
CAT:
804-HY-66011S-01
Size:
10 mg
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


rac cis-Moxifloxacin-d4 (hydrochloride)
UNSPSC Description:
rac cis-Moxifloxacin-d4 (hydrochloride) is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin Hydrochloride (BAY 12-8039) is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].Target Antigen:
Antibiotic; Bacterial; Isotope-Labeled CompoundsType:
Isotope-Labeled CompoundsRelated Pathways:
Anti-infection;OthersField of Research:
InfectionSolubility:
10 mM in DMSOSmiles:
O(C)C1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N3C([C@]4([C@@](C3([2H])[2H])(NCCC4)[H])[H])([2H])[2H])C5CC5.ClMolecular Weight:
441.92References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Culley CM, et al. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm. 2001 Mar 1;58(5):379-88.|[3]Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39.|[4]Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702.|[5]Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102.Shipping Conditions:
Room temperatureClinical Information:
No Development ReportedCAS Number:
1217802-65-7
